Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/12/2024 | $45.00 → $50.00 | Buy | Maxim Group |
9/18/2024 | $45.00 | Buy | Maxim Group |
2/22/2023 | $3.00 | Outperform | Northland Capital |
HOUSTON, May 7, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of the stock market on Tuesday, May 13, 2025. The Company will discuss those results on a conference call on Wednesday, May 14, 2025, at 10:30 a.m. ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=com
HOUSTON, March 17, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the fourth quarter and year ended December 31, 2024 after the close of the stock market on March 27th, 2025. The Company will discuss those results on a conference call on Friday, March 28st, 2025, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://viavid.webcasts.com/starthere.jsp?ei=1706653&tp_key=5e3e4c2f6
HOUSTON, Nov. 5, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 10 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the third quarter ended September 30, 2024 after the close of the stock market on Thursday, November 7, 2024. The Company will discuss those results on a conference call on Friday, November 8, 2024, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant webcast: https://viavid.webcasts.com/starthere.jsp?ei=1691722&tp_key=bfd69ce
HOUSTON, June 2, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the availability of its definitive proxy materials for its 2025 annual meeting to be held on July 14, 2025 at 10:00 am Central Time via the internet as a virtual meeting only (and not in person) at www.virtualshareholdermeeting.com/NUTX2025. We look forward to hosting you at our virtual shareholder meeting and encourage you to participate and vote. Commenc
HOUSTON, May 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm to replace CBIZ CPAs ("CBIZ"), effective May 15, 2025. The change of the Company's independent auditor was made after careful consideration and an evaluation process and was approved by the Audit Committee and the Board of Directors of the
TOTAL REVENUE OF $211.8 MILLION VERSUS $67.5 MILLION IN Q1 2024, AN INCREASE OF 213.8%NET INCOME ATTRIBUTABLE TO NUTEX HEALTH INC. OF $14.6 MILLION VERSUS NET LOSS OF $0.4 MILLION IN Q1 2024DILUTED EPS OF $2.56 PER SHARE VERSUS $(0.08) PER SHARE IN Q1 2024EBITDA OF $43.1 MILLION VERSUS $7.1 MILLION IN EBITDA IN Q1 2024, AN INCREASE OF 507.0%ADJUSTED EBITDA OF $72.8 MILLION VERSUS $(0.4) MILLION IN Q1 2024NET CASH FROM OPERATING ACTIVITIES OF $51.0 MILLIONCOMPANY BELIEVES ITS ARBITRATION EFFORTS THROUGH THE INDEPENDENT DISPUTE RESOLUTION (IDR) PROCESS HAVE RESULTED IN MORE FAIR AND REASONABLE PAYMENTSHOUSTON, May 13, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NA
Maxim Group reiterated coverage of Nutex Health with a rating of Buy and set a new price target of $50.00 from $45.00 previously
Maxim Group initiated coverage of Nutex Health with a rating of Buy and set a new price target of $45.00
Northland Capital initiated coverage of Nutex Health with a rating of Outperform and set a new price target of $3.00
4 - Nutex Health, Inc. (0001479681) (Issuer)
4 - Nutex Health, Inc. (0001479681) (Issuer)
4 - Nutex Health, Inc. (0001479681) (Issuer)
HOUSTON, May 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm to replace CBIZ CPAs ("CBIZ"), effective May 15, 2025. The change of the Company's independent auditor was made after careful consideration and an evaluation process and was approved by the Audit Committee and the Board of Directors of the
HOUSTON, April 22, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 9 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Scott J. Saunders, and Kelvin Spears, MD, to its Board of Directors. They replace John Waters, who recently passed away, and Dr. Daniel Stites, who fulfilled his one-year term Board commitment. The Board has determined that Mr. Saunders satisfies the current independent director standards established by the rules of The Nasdaq Stock Market. Mr. Saunders will s
HOUSTON, Sept. 5, 2023 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Joshua DeTillio as the Company's Chief Operating Officer effective on or about October 2, 2023. Mr. DeTillio is an experienced healthcare leader with over 20 years of hospital experience and 12 years as a CEO in investor-owned, publicly traded companies. He has demonstrated success in collaborating with and leading boards and physicians to drive growth, improve c
SC 13G - Nutex Health, Inc. (0001479681) (Subject)
SC 13G/A - Nutex Health, Inc. (0001479681) (Subject)
SC 13G - Nutex Health, Inc. (0001479681) (Subject)
DEFA14A - Nutex Health, Inc. (0001479681) (Filer)
DEFA14A - Nutex Health, Inc. (0001479681) (Filer)
DEF 14A - Nutex Health, Inc. (0001479681) (Filer)
4 - Nutex Health, Inc. (0001479681) (Issuer)
4 - Nutex Health, Inc. (0001479681) (Issuer)
4 - Nutex Health, Inc. (0001479681) (Issuer)